Top Industry Leaders in the Structural Heart Devices Market
Latest Structural Heart Devices Companies Update
October 2023: Abbott disclosed information regarding the efficacy of its minimally invasive cardiac devices in the treatment of mitral and tricuspid valve disease, derived from late-breaking presentations. The data encompass results obtained from the pivotal trial TRILUMINATE™, which provide further support for the safety and efficacy of the TriClip™ transcatheter edge-to-edge repair (TEER) system in cases where patients have developed severe symptomatic tricuspid regurgitation (TR) despite receiving optimal medical treatment. Additionally, the organization disclosed novel findings from the MitraClip™ EXPAND G4 real-world registry that underscore the advantages of the apparatus among a wide spectrum of patients afflicted with mitral regurgitation. In patients with MR and TR, leaking valves can lessen the volume of blood circulated through the body and cause the heart to work harder than it should. Subsequently, MR and TR can precipitate additional cardiovascular complications and significantly impair an individual's overall well-being.
October 2023: FEops, a prominent entity in personalized predictive planning for structural heart interventions, declared its collaboration with TeraRecon from ConcertAI to facilitate the commercialization of the Left Atrial Appendage (LAA) occlusion workflow of FEops HEARTguide. The collaboration will primarily target the United States market. Utilizing digital twin technology, FEops HEARTguide™ is an unprecedented cloud-based procedure planning solution in the structural heart industry. With the introduction of the LAA occlusion workflow in the United States, FEops HEARTguide™ empowers physicians in the United States to virtually simulate clinical scenarios involving FDA-approved LAA devices in various implant positions and sizes. This tool assists physicians in determining the most suitable size and position for each patient prior to performing the intervention.List of Structural Heart Devices Key companies in the market
- Edwards Lifesciences Corporation (US)
- Medtronic plc (Ireland)
- Abbott (US)
- Boston Scientific Corporation (US)
- LivaNova plc (UK)
- Jude Medical
- Biometrics
- Come BV
- JenaValve Technology Inc.
- CardioKinetix
- Cook Group Incorporated (US)